• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: anthrax immune globulin (human)
Trade Name:
Date Designated: 07/29/2008
Orphan Designation: Treatment of inhalational anthrax
Orphan Designation Status: Designated/Approved
Cangene Corp. - Emergent Biosolutions
155 Innovation Drive
R3T 5Y3
Winnipeg, MB
Canada

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: anthrax immune globulin (human)
Trade Name:
Marketing Approval Date: 03/24/2015
Approved Labeled Indication: Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs
Exclusivity End Date: 03/24/2022 
Exclusivity Protected Indication* :  Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-